drugset / Trial / NCT00093366
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase 1/2
Completed
32 enrolled
Fred Hutchinson Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies such as etanercept may interfere with the growth of the cancer cells. Combining chemotherapy with biological therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects of giving arsenic trioxide together with etanercept and to see how well it works in treating patients with myelodysplastic syndromes.
Timeline
- Start
- 2004-06
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | — | Subcutaneous |
| Subject | arsenic trioxide | Small molecule | — | Intravenous |